Calcimed-D3

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calcimed-D3

Quick Facts: Calcimed-D3 Overview

Property Description
Active Ingredients Calcium Carbonate, Dihydrotachysterol
Form Oral preparation (typically tablet)
Pharmacological Class Calcitropic agent; Combination mineral supplement and Vitamin D analog preparation
General Purpose Supports calcium homeostasis and bone mineralization
Origin Mineral and Synthetic analog

Calcimed-D3: Definition and Pharmacological Classification

Calcimed-D3 is classified as a combination drug and a calcitropic agent, formulated to support the body’s essential calcium homeostasis.

This medication is an oral preparation that combines a core essential mineral with a regulatory compound, placing it in the broader pharmacological class of mineral supplements and Vitamin D analog preparations. Its identity as a combination product is significant, as it addresses the need for the mineral itself and the biological factor required for its processing. Dihydrotachysterol is a synthetic analog used in the management of calcitriol deficiency and related disorders. The preparation consists of both a natural component (Calcium Carbonate) and a synthetic compound (Dihydrotachysterol) and is designed for ingestion to support skeletal mineral status.

Compositional Identity: Calcium Carbonate and Dihydrotachysterol

The active ingredients in Calcimed-D3 are Calcium Carbonate and Dihydrotachysterol.

As a solid oral preparation (typically a tablet), the medication delivers Calcium Carbonate, which serves as the principal source of elemental calcium. The distinction lies with Dihydrotachysterol, which is a high-efficacy synthetic Vitamin D analog rather than natural Vitamin D. This specific combination of the mineral and the synthetic analog is intended to facilitate calcium absorption. The preparation utilizes the interaction between calcium and an analog form of Vitamin D to support intestinal calcium absorption.

General Therapeutic Purpose for Bone Health

The general purpose of Calcimed-D3 is to provide foundational support for maintaining strong bone health and mineral stability.

This calcitropic agent assists the body in balancing both calcium and phosphorus levels, which is crucial for skeletal structure. A neutral use scenario for this combination involves supplementing the nutritional intake for individuals whose calcium homeostasis is compromised. By providing a supply and promoting the uptake of calcium, the medication supports the processes required for the normal mineralization of bone, which is essential for maintaining bone density.

What side effects are possible with Calcimed-D3?

Possible Side Effects and Safety Information

The safety profile of Calcimed-D3 is characterized by the potential for effects related to calcium imbalance, a direct consequence of combining elemental calcium with a Vitamin D analog. The primary safety concerns documented in regulatory information center on elevated calcium levels.


Adverse Reaction Classification

Side effects are officially classified by their frequency and the body system affected (System-Organ Class or SOC).

  • Metabolism and Nutrition Disorders: The most critical documented safety concern is hypercalcemia (elevated serum calcium) and hypercalciuria (excess calcium in the urine), which are dose-dependent risks.
  • Gastrointestinal Disorders: Effects such as constipation, flatulence, and abdominal pain are commonly listed.
  • Renal and Urinary Disorders: These include hypercalciuria and, in rare instances associated with chronic, uncontrolled calcium levels, the risk of nephrocalcinosis (calcium deposits in the kidneys).

Documented Serious Adverse Reactions

The most clinically significant adverse reactions explicitly documented in regulatory sources include marked hypercalcemia and the long-term risk of nephrocalcinosis. The label also notes the potential for severe hypersensitivity reactions, although these are categorized as very rare.


Safety Considerations for Special Populations and Long-Term Use

Official regulatory documents emphasize specific safety constraints for certain patient groups. Individuals with renal impairment are documented as having an increased risk of hypercalcemia. Furthermore, the label mandates the monitoring of serum calcium levels and renal function as an essential safety protocol, particularly during prolonged or high-dose therapy, due to the documented association between long-term exposure and potential renal complications.

Overdose and Emergency Response

Overdose and When to Seek Help

The official documentation for Calcimed-D3 overdose focuses on the pathological condition of hypercalcemia resulting from excessive intake of the calcitropic components. Regulatory sources document that overdose may present with initial signs such as nausea, vomiting, anorexia, metallic taste, and disturbances in fluid balance like polyuria and polydipsia. As the condition progresses, central nervous system manifestations such as headache, somnolence, and confusion are officially noted.

Serious Manifestations and Mandated Action

The regulatory profile classifies severe outcomes that include systemic organ toxicity. Documented severe complications are nephrocalcinosis, potential kidney failure, and serious cardiac arrhythmias. Due to these risks, regulators mandate that individuals must seek immediate medical attention upon suspicion of an overdose or if any symptoms of hypercalcemia appear. Urgent medical care is required for life-threatening manifestations, particularly those affecting the cardiovascular or nervous systems. A population-specific note highlights an increased risk of severity in patients with pre-existing renal impairment.

Management and Monitoring Requirements

The required management procedure involves the immediate discontinuation of Calcimed-D3. Treatment is specified as symptomatic and supportive. Hospital monitoring is required, including observation of serum calcium levels, renal function, and ECG to detect cardiac effects. The official labeling confirms that no specific antidote is known for the active ingredients.

Therapeutic Uses of Calcimed-D3

Quick Facts: What Calcimed-D3 Treats

  • Addresses: Low blood calcium levels (hypocalcemia).
  • Supports: The nutritional requirements of the body for calcium and vitamin D.
  • Assists in Management of: Conditions related to low calcium, such as bone loss (osteoporosis) and weak bones (osteomalacia/rickets).

What Calcimed-D3 Treats: Main Uses and Benefits

Calcimed-D3 is used to manage low blood calcium levels in individuals who may not obtain sufficient calcium from their regular diets. This medication may be prescribed to address the body's nutritional requirements for both calcium and vitamin D.

In a therapeutic context, the medication assists in the management of specific conditions that result from insufficient calcium levels. These conditions include osteoporosis (bone loss) and osteomalacia or rickets (weakening of bones). These components are involved in maintaining the functioning of the nerves, cells, muscles, and bones. Adequate levels of calcium and vitamin D support the building and maintenance of strong bones. This medication may also be used to support the requirements of certain patient populations, including those with decreased activity of the parathyroid gland.

Regulatory References

  1. NIH MedlinePlus guidance on Calcium and Vitamin D

Eligibility and Restrictions for Use

Who Can and Cannot Use Calcimed-D3?

This medication has established eligibility criteria based on official regulatory labeling, primarily defining who must not use the medicine (contraindications) and who requires use under specific restrictions. The primary eligible population includes adults and the elderly requiring support for bone health, especially those with conditions like hypoparathyroidism.

Absolute Prohibitions (Contraindications)

Calcimed-D3 is strictly contraindicated and must not be used by patients with:

  • Pre-existing hypercalcemia (high blood calcium levels), including that resulting from conditions like myeloma.
  • Hypervitaminosis D (excessive Vitamin D levels).
  • Severe renal impairment or severe renal failure.
  • Known hypersensitivity to Calcium Carbonate, Dihydrotachysterol, or any of the product’s excipients.

Restricted and Conditional Use

Use is conditional and requires close medical supervision for patients with mild to moderate renal impairment or a history of kidney stones.

Caution is also mandated for individuals with conditions like sarcoidosis or certain malignancies due to the elevated risk of hypercalcemia. Furthermore, the medicine is generally not recommended for children under the age of 12 for routine supplementation. Use during pregnancy is permitted only if the potential benefit is judged to outweigh the possible risks, and use while breastfeeding is usually not recommended and requires caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Calcimed-D3, a combination of Calcium and Vitamin D, can interact with certain medications and supplements, primarily by altering their absorption or increasing the risk of high blood calcium levels (hypercalcemia).

Interacting Product Category Potential Effect and Constraint
Tetracycline & Quinolone Antibiotics (e.g., Ciprofloxacin, Doxycycline) Calcium can decrease the absorption of these medicines. Doses must be separated by several hours.
Cardiac Glycosides (e.g., Digoxin) Increased calcium levels may potentiate the effects, heightening the risk of an abnormal heartbeat. Close monitoring is necessary.
Thiazide Diuretics (e.g., Bendroflumethiazide) These diuretics reduce calcium excretion, and the combination can significantly increase the risk of hypercalcemia.
Anticonvulsants (e.g., Phenytoin, Carbamazepine) These medicines can increase the breakdown (metabolism) of Vitamin D, potentially necessitating a higher Calcimed-D3 dose.
Corticosteroids (e.g., Prednisolone) These medications may reduce the effects of the Vitamin D component, possibly requiring dose adjustment.
Bile Acid Sequestrants (e.g., Cholestyramine) & Mineral Oil These agents can decrease the absorption of Vitamin D.
Other Calcium or Vitamin D Products (e.g., Calcitriol) Generally avoided due to the high risk of severe hypercalcemia.

To minimize interaction risk, it is important to separate the intake of Calcimed-D3 from medicines whose absorption may be affected, such as levothyroxine and bisphosphonates. Additionally, foods high in oxalic or phytic acid (e.g., spinach, whole grains) may also reduce calcium absorption and should be spaced apart from the supplement when possible.

Mechanism of Action

Mechanism of Action: Dual Modulation of Calcium and Phosphate

Calcimed-D3 is a combination therapy that acts primarily by modulating calcium homeostasis. Its dual-action mechanism influences whole-body mineral metabolism through the synergistic effects of its components.

The calcitriol component initiates an upregulation of the intestinal Ca^2+/Phosphate cotransporter expression, thereby increasing the rate of Ca^2+ absorption from the gastrointestinal tract. Concurrently, it acts on the renal distal tubules to inhibit the reabsorption of phosphate, promoting its urinary excretion. This coordinated action results in the modulation of the serum calcium-to-phosphate ratio.

The cholecalciferol component is a precursor. It undergoes essential sequential metabolic processes: initial hepatic 25-hydroxylation followed by subsequent renal 1-alpha-hydroxylation to replenish calcitriol stores. This entire mechanistic cascade contributes to the regulation of calcium metabolism and influences the maintenance of skeletal tissue structure.

Dosage and Administration Information

Calcimed-D3 is an oral preparation used to achieve therapeutic control over calcium levels. Use follows a structured, individualized approach based on the Dihydrotachysterol component.

Administration Guidelines

Category Labeled Instruction
Route of Administration Oral ingestion only (tablet or solution).
Dosing Schedule Once daily (q.d.). The regimen includes a distinct, short-term Initial/Loading Dose that transitions to a long-term Maintenance Dose.
Timing in Relation to Meals May be taken with or without food.

Procedural and Dosing Requirements

Dosing is dependent on monitoring and titration, requiring the dose to be individualized for each patient. The typical dosage involves an Initial Dose, for example, of 0.8 mg to 2.4 mg of Dihydrotachysterol daily for several days, followed by a Maintenance Dose that typically ranges from 0.2 mg to 1.0 mg daily. The Calcium Carbonate component provides concurrent intake of elemental calcium.

  • Dose Adjustment: Dosage adjustments are typically made at intervals of 4 to 8 weeks to allow for stable metabolic effects before further changes.
  • Monitoring Constraint: Therapy involves monitoring of serum calcium levels (e.g., weekly during initial titration, then monthly) to guide dosage changes and ensure the therapeutic range is maintained.
  • Pediatric Use: Specific initial and maintenance dosing schedules, which may be higher on a milligram-per-day basis for the Dihydrotachysterol component, are utilized for the treatment of infants and children.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Calcimed-D3

Evidence for Managing Low Blood Calcium (Hypocalcemia)

The research examined the components of Calcimed-D3 (calcium carbonate and a synthetic Vitamin D analog) in the context of low blood calcium levels (hypocalcemia). These studies was evaluated in populations of adults and children who had low calcium due to various causes. The main outcomes examined focused on the achievement and maintenance of target calcium levels in the blood (measured serum calcium) and study outcomes related to physical discomfort.

Studies monitored how serum calcium levels evolved in the observed populations. The research noted that the potential for high blood calcium (hypercalcemia), linked to the Vitamin D analog, means that close monitoring and adjustment of the compound was observed in some studies.

Evidence Supporting Bone Health and Osteoporosis

Research examined the use of Calcimed-D3 components in the context of bone loss (osteoporosis). The research was evaluated in older adult populations. Key studies included large-scale, long-term Randomized Controlled Trials (RCTs) and comprehensive meta-analyses.

The main outcomes examined in these studies included measured changes in Bone Mineral Density (BMD) and data show patterns related to the occurrence of fractures. Findings describe patterns observed in the studies where measured changes in BMD were reported. Evidence quality varies across studies regarding the patterns of fracture prevention, particularly in community-dwelling individuals. This means the certainty remains low for broad, definitive statements about fracture occurrence across all subgroups.

What is Still Uncertain About Calcimed-D3 Research

Research highlights what is known — and what is still uncertain. The major uncertainty lies in the inconsistent findings reported across different high-quality studies regarding the observed patterns of calcium and Vitamin D analogs on all types of fractures. Long-term effects are not fully established regarding the durability of the effect after many years of use. Further research is ongoing to address remaining evidence gaps.

Frequently Asked Questions (FAQ)

Common questions about Calcimed-D3 (FAQ)


Q: Does Calcimed-D3 help with bone density problems?

A: The components of Calcimed-D3 are studied for use in the context of conditions affecting bone health, such as hypoparathyroidism and osteoporosis. These conditions are often associated with low bone density. The medicine is intended to support the calcium and mineral balance required for skeletal structure.


Q: Are there any common reasons people stop taking Calcimed-D3?

A: Regulatory documents indicate that a common reason for temporarily withholding or discontinuing this medicine is the development of hypercalcemia, meaning excessively high calcium levels in the blood. Since the risk of hypercalcemia is dose-dependent, close monitoring is a required procedure for managing the continuation of the therapy.


Q: Is it possible to take too much Calcimed-D3?

A: Yes, taking more than the prescribed amount can lead to toxicity, described as hypervitaminosis D and hypercalcemia (excessively high blood calcium). Symptoms of taking too much may appear slowly and can include increased thirst, frequent urination, and severe stomach discomfort. The regulatory procedure described in these circumstances is to withhold the medicine and seek appropriate medical guidance.


Q: Does taking Calcimed-D3 affect how blood tests look?

A: Yes, one of the primary requirements for this therapy is the frequent monitoring of serum calcium levels in the blood. Uncontrolled high calcium levels (hypercalcemia) can also influence other related blood markers, such as those related to kidney function (renal insufficiency) and overall electrolyte balance.


Q: What happens if I miss a dose of Calcimed-D3?

A: Patient instructions provided by authoritative sources generally advise taking the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. The typical recommendation is that two doses should not be taken at the same time to avoid an excessive intake.


Q: Is Calcimed-D3 a brand name or a generic name for the ingredients?

A: Calcimed-D3 is a brand name that refers to a combination of active ingredients. These ingredients are Calcium Carbonate and the synthetic regulatory compound Dihydrotachysterol. Dihydrotachysterol itself may be available under other brand names.


Q: Can someone with lactose intolerance safely use Calcimed-D3?

A: The ingredients lists for this class of medicine often contain inactive ingredients (excipients) that vary between specific products. To determine the presence of ingredients like lactose, reference to the specific product's package insert is advised, as excipients can vary by formulation.


Q: What are the signs that Calcimed-D3 might not be working for someone?

A: As the medicine is used to maintain healthy mineral levels, signs it may not be working could align with persistent or recurring symptoms of low calcium (hypocalcemia). These may include muscle twitching, numbness, or tingling sensations. However, monitoring blood tests remains the primary method for assessing effectiveness, as stated in official monitoring guidelines.


Q: Does the time of day matter when taking Calcimed-D3?

A: Official administration guidelines state that the medicine may be taken with or without food. While the specific time of day is not typically critical, official guidance recommends consistent daily timing to help maintain stable blood levels for chronic therapy.


Q: Are there different strengths of Calcimed-D3 available?

A: Yes. The active component Dihydrotachysterol is generally available in several oral strengths, such as 0.125 mg, 0.2 mg, and 0.4 mg tablets, as well as an oral solution formulation. Regulatory documents state that the selection of the dose strength is individualized based on specific treatment requirements.


Q: What is the typical duration of treatment with Calcimed-D3?

A: For chronic conditions like hypoparathyroidism, which require continuous calcium management, treatment with the components of Calcimed-D3 is often considered a long-term or potentially lifelong therapy. The dosage is individualized and adjusted over intervals of several weeks or months.


Q: Is it true that Calcimed-D3 is only for people with severe deficiencies?

A: Official uses for this medicine include the management of conditions like hypoparathyroidism and rickets. While these can involve severe deficiencies, the medicine is indicated for managing underlying calcium imbalances across a range of severities, not exclusively for the most severe cases.


Q: Can Calcimed-D3 cause allergic reactions?

A: Yes, official regulatory documents note the potential for severe hypersensitivity reactions (allergic reactions), although this is categorized as a rare occurrence. Signs of an allergic reaction may include hives, difficulty breathing, or swelling of the face, lips, or tongue.


Q: What research themes are commonly associated with Calcimed-D3?

A: Major research themes described in official documents center on the management of hypocalcemia (low calcium), hypoparathyroidism, and related bone disorders. This includes addressing conditions like osteoporosis and kidney-related bone disease (renal osteodystrophy).


Q: Does Calcimed-D3 affect mood?

A: While mood changes are not listed as a common side effect of the medicine itself, hypercalcemia (excessively high blood calcium) is a serious potential adverse reaction. As a late symptom of hypercalcemia, regulatory sources mention the possibility of effects like mental confusion and mood changes.


Q: Is Calcimed-D3 used as a preventative measure for certain conditions?

A: The medicine is primarily indicated for the treatment of conditions such as hypocalcemia and hypoparathyroidism. Its role is therapeutic, aimed at correcting and maintaining calcium and bone mineral balance in patients whose existing condition compromises their mineral status.


Q: How long does Calcimed-D3 stay in the body?

A: The effects of the Vitamin D analog component can persist for a prolonged period after the treatment has been stopped. Regulatory information for similar agents suggests that effects can last for two or more months due to how the compound is accumulated and slowly metabolized by the body.

How should Calcimed-D3 be stored and disposed of?

This medication must be handled and stored according to strict regulatory conditions to ensure its stability.

Storage Requirements

  • Temperature and Light: Store in a cool, dry, and dark place at a temperature not exceeding 25 C or 30 C, as specified by the product license. The product must be protected from light and moisture.
  • Packaging: Keep the medicine in its original container and ensure the container or blister packaging remains tightly closed.
  • Child Safety: It is a regulatory requirement to keep Calcimed-D3 out of the sight and reach of children.

Disposal Instructions

  • Unused Product: Dispose of any unused or expired product strictly in accordance with local regulatory requirements.
  • Wastewater: Do not dispose of the medication by throwing it into the household trash or washing it into the sewer system or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calcimed-D3 found in:

A-Z Index: